Eli Lilly and Company (LLY)vsOSR Holdings Inc (OSRH)
LLY
Eli Lilly and Company
$1,115.70
-0.65%
HEALTHCARE · Cap: $994.92B
OSRH
OSR Holdings Inc
$0.20
+0.55%
HEALTHCARE · Cap: $9.73M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 4404500% more annual revenue ($79.67B vs $1.81M). LLY leads profitability with a 33.5% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
OSRH
Avoid25
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -14.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : OSRH
The strongest argument for OSRH centers on Price/Book, Debt/Equity.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : OSRH
The primary concerns for OSRH are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
LLY profiles as a growth stock while OSRH is a value play — different risk/reward profiles.
OSRH carries more volatility with a beta of 0.56 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 25/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →OSR Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
OSR Holdings Inc. is a prominent provider of integrated managed services, offering specialized asset management and financial advisory solutions tailored for institutional clients. By harnessing advanced technology and strategic partnerships, the company enhances operational efficiency while expanding its diverse array of services. With a commitment to sustainable growth and a client-centric approach, OSR Holdings distinguishes itself through innovative strategies and exceptional service quality. The firm maintains a proactive focus on emerging market opportunities and employs a comprehensive risk management framework, positioning it strategically for long-term stability and success for its stakeholders.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?